Table Info

S. No.	Protein pair	Etotal (kJ mol^–1)
1	Myocilin and β-amyloid	–724.1
2	Optineurin and β-amyloid	–296.9
3	Mutated optineurin and β-amyloid	–607.1

Supplementary materials

The supplementary materials for this article is available at: https://www.explorationpub.com/uploads/Article/file/100818_sup_1.pdf.

Declarations

Acknowledgment

The author acknowledges Prof. Mahendra Kumar, Principal, Government Shrimant Madhavrao Scindia PG College, Shivpuri, Madhya Pradesh 473551, India, for providing necessary facilities to conduct this work.

Author contributions

NM: Conceptualization, Data curation, Writing—original draft, Writing—review & editing.

Conflicts of interest

The author declares that she has no conflicts of interest.

Ethical approval

Not applicable.

Consent to participate

Not applicable.

Consent to publication

Not applicable.

Availability of data and materials

Not applicable.

Funding

Not applicable.

Copyright

References

Sisodia SS, Price DL. Role of the β-amyloid protein in Alzheimer’s disease. FASEB J. 1995;9:366–70. [DOI] [PubMed]

Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, et al. The precursor of Alzheimer’s disease amyloid A4 protein resembles a cell-surface receptor. Nature. 1987;325:733–6. [DOI] [PubMed]

Yacoubian TA. Chapter 1 - Neurodegenerative disorders: why do we need new therapies? In: Adejare A, editor. Drug discovery approaches for the treatment of neurodegenerative disorders. Academic Press. 2017. pp. 1–16.

Mendez MF, McMurtray AM. Neurodegenerative disorders. In: Fink G, editor. Encyclopedia of stress (second edition). 2nd. New York: Academic Press; 2007. pp. 840–4.

Bozyczko-Coyne D, Williams M. 6.08 – Neurodegeneration. In: Taylor JB, Triggle DJ, editors. Comprehensive medicinal chemistry II. Oxford: Elsevier. 2007. pp. 193–228.

Wostyn P, Audenaert K, De Deyn PP. Alzheimer’s disease and glaucoma: is there a causal relationship? Br J Ophthalmol. 2009;93:1557–9. [DOI] [PubMed]

Wang L, Mao X. Role of retinal amyloid-β in neurodegenerative diseases: overlapping mechanisms and emerging clinical applications. Int J Mol Sci. 2021;22:2360. [DOI] [PubMed] [PMC]

Wang HW, Sun P, Chen Y, Jiang LP, Wu HP, Zhang W, et al. Research progress on human genes involved in the pathogenesis of glaucoma (review). Mol Med Rep. 2018;18:656–74. [DOI] [PubMed] [PMC]

Hill SE, Nguyen E, Donegan RK, Patterson-Orazem AC, Hazel A, Gumbart JC, et al. Structure and misfolding of the flexible tripartite coiled-coil domain of glaucoma-associated myocilin. Structure. 2017;25:1697–707.e5. [DOI] [PubMed] [PMC]

10.

Katoli P, Godbole A, Romanowski MJ, Clark K, Meredith E, Saenz-Vash V, et al. Full-length myocilin protein is purified from mammalian cells as a dimer. Protein Expr Purif. 2018;147:38–48. [DOI] [PubMed]

11.

Nguyen TD, Chen P, Huang WD, Chen H, Johnson D, Polansky JR. Gene structure and properties of TIGR, an olfactomedin-related glycoprotein cloned from glucocorticoid-induced trabecular meshwork cells. J Biol Chem. 1998;273:6341–50. [DOI] [PubMed]

12.

Kubota R, Noda S, Wang Y, Minoshima S, Asakawa S, Kudoh J, et al. A novel myosin-like protein (myocilin) expressed in the connecting cilium of the photoreceptor: molecular cloning, tissue expression, and chromosomal mapping. Genomics. 1997;41:360–9. [DOI] [PubMed]

13.

Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SLF, et al. Identification of a gene that causes primary open angle glaucoma. Science. 1997;275:668–70. [DOI] [PubMed]

14.

Adam MF, Belmouden A, Binisti P, Brézin AP, Valtot F, Béchetoille A, et al. Recurrent mutations in a single exon encoding the evolutionarily conserved olfactomedin-homology domain of TIGR in familial open-angle glaucoma. Hum Mol Genet. 1997;6:2091–7. [DOI] [PubMed]

15.

Ortego J, Escribano J, Coca-Prados M. Cloning and characterization of subtracted cDNAs from a human ciliary body library encoding TIGR, a protein involved in juvenile open angle glaucoma with homology to myosin and olfactomedin. FEBS Lett. 1997;413:349–53. [DOI] [PubMed]

16.

Torrado M, Trivedi R, Zinovieva R, Karavanova I, Tomarev SI. Optimedin: a novel olfactomedin-related protein that interacts with myocilin. Hum Mol Genet. 2002;11:1291–301. [DOI] [PubMed]

17.

Ohlmann A, Goldwich A, Flügel-Koch C, Fuchs AV, Schwager K, Tamm ER. Secreted glycoprotein myocilin is a component of the myelin sheath in peripheral nerves. Glia. 2003;43:128–40. [DOI] [PubMed]

18.

Swiderski RE, Ross JL, Fingert JH, Clark AF, Alward WL, Stone EM, et al. Localization of MYOC transcripts in human eye and optic nerve by in situ hybridization. Invest Ophthalmol Vis Sci. 2000;41:3420–8. [PubMed]

19.

Polansky JR, Fauss DJ, Chen P, Chen H, Lütjen-Drecoll E, Johnson D, et al. Cellular pharmacology and molecular biology of the trabecular meshwork inducible glucocorticoid response gene product. Ophthalmologica. 1997;211:126–39. [DOI] [PubMed]

20.

Tamm ER, Russell P, Epstein DL, Johnson DH, Piatigorsky J. Modulation of myocilin/TIGR expression in human trabecular meshwork. Invest Ophthalmol Vis Sci. 1999;40:2577–82. [PubMed]

21.

Ueda J, Wentz-Hunter KK, Cheng EL, Fukuchi T, Abe H, Yue BY. Ultrastructural localization of myocilin in human trabecular meshwork cells and tissues. J Histochem Cytochem. 2000;48:1321–9. [DOI] [PubMed]

22.

Filla MS, Liu X, Nguyen TD, Polansky JR, Brandt CR, Kaufman PL, et al. In vitro localization of TIGR/MYOC in trabecular meshwork extracellular matrix and binding to fibronectin. Invest Ophthalmol Vis Sci. 2002;43:151–61. [PubMed]

23.

Ying H, Yue BYJT. Chapter five - Cellular and molecular biology of optineurin. In: Jeon KW, editor. International review of cell and molecular biology. Academic Press. 2012. pp. 223–58. [DOI] [PubMed] [PMC]

24.

Li Y, Kang J, Horwitz MS. Interaction of an adenovirus E3 14.7-kilodalton protein with a novel tumor necrosis factor alpha-inducible cellular protein containing leucine zipper domains. Mol Cell Biol. 1998;18:1601–10. [DOI] [PubMed] [PMC]

25.

Rezaie T, Waitzman DM, Seeman JL, Kaufman PL, Sarfarazi M. Molecular cloning and expression profiling of optineurin in the rhesus monkey. Invest Ophthalmol Vis Sci. 2005;46:2404–10. [DOI] [PubMed]

26.

Nagabhushana A, Chalasani ML, Jain N, Radha V, Rangaraj N, Balasubramanian D, et al. Regulation of endocytic trafficking of transferrin receptor by optineurin and its impairment by a glaucoma-associated mutant. BMC Cell Biol. 2010;11:4. [DOI] [PubMed] [PMC]

27.

Park BC, Shen X, Samaraweera M, Yue BYJT. Studies of optineurin, a glaucoma gene: Golgi fragmentation and cell death from overexpression of wild-type and mutant optineurin in two ocular cell types. Am J Pathol. 2006;169:1976–89. [DOI] [PubMed] [PMC]

28.

Ying H, Yue BYJT. Optineurin: the autophagy connection. Exp Eye Res. 2016;144:73–80. [DOI] [PubMed] [PMC]

29.

Perera DDBD, Perera KML, Peiris DC. A novel in silico benchmarked pipeline capable of complete protein analysis: a possible tool for potential drug discovery. Biology (Basel). 2021;10:1113. [DOI] [PubMed] [PMC]

30.

Macindoe G, Mavridis L, Venkatraman V, Devignes MD, Ritchie DW. HexServer: an FFT-based protein docking server powered by graphics processors. Nucleic Acids Res. 2010;38:W445–9. [DOI] [PubMed] [PMC]

31.

Agrawal P, Singh H, Srivastava HK, Singh S, Kishore G, Raghava GPS. Benchmarking of different molecular docking methods for protein-peptide docking. BMC Bioinformatics. 2019;19:426. [DOI] [PubMed] [PMC]

32.

Ritchie DW. Recent progress and future directions in protein-protein docking. Curr Protein Pept Sci. 2008;9:1–15. [DOI] [PubMed]

33.

Mavridis L, Hudson BD, Ritchie DW. Toward high throughput 3D virtual screening using spherical harmonic surface representations. J Chem Inf Model. 2007;47:1787–96. [DOI] [PubMed]

34.

Lührs T, Ritter C, Adrian M, Riek-Loher D, Bohrmann B, Döbeli H, et al. 3D structure of Alzheimer’s amyloid-β(1-42) fibrils. Proc Natl Acad Sci U S A. 2005;102:17342–7. [DOI] [PubMed] [PMC]

35.

Donegan RK, Hill SE, Freeman DM, Nguyen E, Orwig SD, Turnage KC, et al. Structural basis for misfolding in myocilin-associated glaucoma. Hum Mol Genet. 2015;24:2111–24. [DOI] [PubMed] [PMC]

36.

Nakazawa S, Oikawa D, Ishii R, Ayaki T, Takahashi H, Takeda H, et al. Linear ubiquitination is involved in the pathogenesis of optineurin-associated amyotrophic lateral sclerosis. Nat Commun. 2016;7:12547. [DOI] [PubMed] [PMC]

37.

Li F, Xie X, Wang Y, Liu J, Cheng X, Guo Y, et al. Structural insights into the interaction and disease mechanism of neurodegenerative disease-associated optineurin and TBK1 proteins. Nat Commun. 2016;7:12708. [DOI] [PubMed] [PMC]

38.

Joe MK, Lieberman RL, Nakaya N, Tomarev SI. Myocilin regulates metalloprotease 2 activity through interaction with TIMP3. Invest Ophthalmol Vis Sci. 2017;58:5308–18. [DOI] [PubMed] [PMC]

39.

Barabási AL, Gulbahce N, Loscalzo J. Network medicine: a network-based approach to human disease. Nat Rev Genet. 2011;12:56–68. [DOI] [PubMed] [PMC]

40.

Ideker T, Sharan R. Protein networks in disease. Genome Res. 2008;18:644–52. [DOI] [PubMed] [PMC]

41.

Huard DJE, Crowley VM, Du Y, Cordova RA, Sun Z, Tomlin MO, et al. Trifunctional high-throughput screen identifies promising scaffold to inhibit Grp94 and treat myocilin-associated glaucoma. ACS Chem Biol. 2018;13:933–41. [DOI] [PubMed] [PMC]

42.

Maurya N, Agarwal NR, Ghosh I. Low-dose rotenone exposure induces early senescence leading to late apoptotic signaling cascade in human trabecular meshwork (HTM) cell line: an in vitro glaucoma model. Cell Biol Int. 2016;40:107–20. [DOI] [PubMed]

43.

Joe MK, Nakaya N, Abu-Asab M, Tomarev SI. Mutated myocilin and heterozygous Sod2 deficiency act synergistically in a mouse model of open-angle glaucoma. Hum Mol Genet. 2015;24:3322–34. [DOI] [PubMed] [PMC]

44.

Anholt RRH, Carbone MA. A molecular mechanism for glaucoma: endoplasmic reticulum stress and the unfolded protein response. Trends Mol Med. 2013;19:586–93. [DOI] [PubMed] [PMC]

45.

Wang Y, Gao Y, Hill SE, Huard DJE, Tomlin MO, Lieberman RL, et al. Simulations and experiments delineate amyloid fibrilization by peptides derived from glaucoma-associated myocilin. J Phys Chem B. 2018;122:5845–50. [DOI] [PubMed] [PMC]

46.

Minegishi Y, Iejima D, Kobayashi H, Chi ZL, Kawase K, Yamamoto T, et al. Enhanced optineurin E50K-TBK1 interaction evokes protein insolubility and initiates familial primary open-angle glaucoma. Hum Mol Genet. 2013;22:3559–67. [DOI] [PubMed]

47.

Liu YH, Tian T. Hypothesis of optineurin as a new common risk factor in normal-tension glaucoma and Alzheimer’s disease. Med Hypotheses. 2011;77:591–2. [DOI] [PubMed]

48.

Chalasani ML, Radha V, Gupta V, Agarwal N, Balasubramanian D, Swarup G. A glaucoma-associated mutant of optineurin selectively induces death of retinal ganglion cells which is inhibited by antioxidants. Invest Ophthalmol Vis Sci. 2007;48:1607–14. [DOI] [PubMed]

49.

Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M, et al. Adult-onset primary open-angle glaucoma caused by mutations in optineurin. Science. 2002;295:1077–9. [DOI] [PubMed]

50.

Park BC, Tibudan M, Samaraweera M, Shen X, Yue BYJT. Interaction between two glaucoma genes, optineurin and myocilin. Genes Cells. 2007;12:969–79. [DOI] [PubMed]

51.

Ying H, Shen X, Park B, Yue BYJT. Posttranslational modifications, localization, and protein interactions of optineurin, the product of a glaucoma gene. PLoS One. 2010;5:e9168. [DOI] [PubMed] [PMC]

52.

Gao J, Ohtsubo M, Hotta Y, Minoshima S. Oligomerization of optineurin and its oxidative stress- or E50K mutation-driven covalent cross-linking: possible relationship with glaucoma pathology. PLoS One. 2014;9:e101206. [DOI] [PubMed] [PMC]

53.

Chalasani ML, Swarup G, Balasubramanian D. Optineurin and its mutants: molecules associated with some forms of glaucoma. Ophthalmic Res. 2009;42:176–84. [DOI] [PubMed]